Cross-Reactive Bactericidal Antimeningococcal Antibodies

The threat from invasive meningococcal disease (IMD) remains a serious source of concern despite the licensure and availability of vaccines. A limitation of current serogroup B vaccines is the breadth of coverage afforded, resulting from the capacity for extensive variation of the meningococcus and its huge potential for the generation of further diversity.

Publication

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

×
As a Guest, you have insight(s) remaining for this month. Create a free account to view 300 more annually.
Related Posts
error: Faculti Content is protected. Please check our Privacy Policy and Terms and Conditions.

Add the Faculti Web App to your Mobile or Desktop homescreen

Install
×